Wanas Y, Bashir R, Islam N, et al. - In VALUE trial, participants taking angiotensin receptor blockers (ARBs) vs other antihypertensive were shown to have an increased risk of myocardial infarction, so, researchers investigated whether ARBs raise the risk of cardiovascular events, by performing this meta-analysis wherein the available evidence of randomised controlled trials (RCTs) was synthetized. They identified RCTs that evaluated the safety of ARBs, via a comprehensive search. They analyzed overall 45 RCTs with 170,794 participants. Findings revealed no increased risk of major cardiovascular events in relation to treatment with ARBs. The results highlighted the safety of ARBs for use in patients.